Janux Therapeutics

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced its upcoming presentation of preclinical data for the Company's two lead TRACTr programs, PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008), in separate poster presentations at the 18th

Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update. “Janux made great strides in 2021 as we transitioned to a public company

Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in three upcoming investor conferences: Cowen's 42nd Annual Health Care Conference Forum: Panel titled “Novel IO” Location: Virtual Date: Monday

Janux Therapeutics to Present at Upcoming March Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Byron Robinson, Ph.D., J.D., as Chief Strategy Officer. Dr. Robinson brings 30 years of industry expertise and experience from key strategy roles at large pharma co

Janux Therapeutics Appoints Byron Robinson, Ph.D., J.D., as Chief Strategy Officer

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference being held January 10 to 13. The fireside chat will be available for on-

Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the quarter ended September 30, 2021. “In the third quarter, we continued to utilize our novel TRACTr and TRACIr platforms to advance our pipeline of next generat

Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in fireside chats at two upcoming virtual investor conferences: Cowen's 5th Annual IO Next Summit Forum: Fireside Chat Date: Monday, November 15

Janux Therapeutics to Present Virtually at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the additions of Ronald W. Barrett, Ph.D., and Alana McNulty as members of the Company's Board of Directors. Dr. Barrett is a scientist entrepreneur with more than 30 years of experie

Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at the virtual H.C. Wainwright 23rd Annual Global Investor Conference being held September 13 to 15, 2021. The corporate presentation will be availa

Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies based on its TRACTr platform technology, today reported financial results for the quarter ended June 30, 2021. “With the successful completions of a Series B financing and IPO this past quarter, we are well-capitalized to advance our novel TRACTr platform technology and next-generation T cell engager immunotherapies, with the potential to impro

Janux Therapeutics Reports Second Quarter 2021 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the appointment of Shahram Salek-Ardakani, Ph.D., as Chief Scientific Officer. Dr. Salek-Ardakani will lead the scientific advancement of Janux's proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to expand Janux's pipeline of next-generation T cell engager immunotherapies. Dr. Salek-Ardakani joins Janux fr

Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer

LA JOLLA, Calif.--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the closing of its previously announced initial public offering of 13,110,000 shares of its common stock, which includes 1,710,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $17.00 per share. Including the option exercise, th

Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Merck

The 37th biotech to hit the public markets this year has a potentially $1 billion deal with Merck & Co. Inc. ( MRK , Financial).

Merck Partners With Newly Public Cancer Biotech

Blue Safari Group Acquisition Corp

Kanzhun Ltd

1stdibs.com

Global Consumer Acquisition Corp

LifeStance Health Group

Logistics Innovation Technologies Corp

monday.com

Marqeta

TaskUS

Zeta Global Holdings Corp

Zhangmen Education

U.S. IPO Weekly Recap: Summer's First Wave Brings 10 IPOs

Janux Therapeutics Inc. received a bullish reception on its Wall Street debut, as shares of the California-based biotechnology company developing cancer treatments opened at double the upsized initial public offering price before paring some gains. The company raised $193.8 million as it sold 11.4 million shares in the IPO, which priced at $17 a share.

Janux Therapeutics stock opens at double the upsized IPO's pricing

The IPO market is ending the week with three deals. Kanzhun, a Chinese job-recruitment app; TaskUs, a digital outsourcer; and biotech Janux Therapeutics are listing their shares Friday.

3 Stocks Make Their Trading Debuts Friday. What Investors Need to Know.

News for Janux Therapeutics Stock (JANX)